Cargando…

Interactions between clinically used drugs and oral contraceptives.

Metabolism of contraceptive compounds may be influenced by various drugs. Of clinical importance is induction by barbiturates, by diphenylhydantoin, and especially by rifampicin, of enzymes that are responsible for degradation of estrogens. The major target is the hepatic microsomal estrogen-2-hydro...

Descripción completa

Detalles Bibliográficos
Autor principal: Bolt, H M
Formato: Texto
Lenguaje:English
Publicado: 1994
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1566787/
https://www.ncbi.nlm.nih.gov/pubmed/7698081
_version_ 1782129692787081216
author Bolt, H M
author_facet Bolt, H M
author_sort Bolt, H M
collection PubMed
description Metabolism of contraceptive compounds may be influenced by various drugs. Of clinical importance is induction by barbiturates, by diphenylhydantoin, and especially by rifampicin, of enzymes that are responsible for degradation of estrogens. The major target is the hepatic microsomal estrogen-2-hydroxylase (cytochrome P450 3A4). Another type of interaction of drugs with disposition and effectiveness of estrogens is impairment of their enterohepatic circulation. This may be due to absorption of biliary estrogen conjugates (e.g., by cholestyramine) or to insufficient cleavage of the conjugate by intestinal bacteria, the latter being observed after administration of antibiotics (e.g., ampicillin, neomycin).
format Text
id pubmed-1566787
institution National Center for Biotechnology Information
language English
publishDate 1994
record_format MEDLINE/PubMed
spelling pubmed-15667872006-09-19 Interactions between clinically used drugs and oral contraceptives. Bolt, H M Environ Health Perspect Research Article Metabolism of contraceptive compounds may be influenced by various drugs. Of clinical importance is induction by barbiturates, by diphenylhydantoin, and especially by rifampicin, of enzymes that are responsible for degradation of estrogens. The major target is the hepatic microsomal estrogen-2-hydroxylase (cytochrome P450 3A4). Another type of interaction of drugs with disposition and effectiveness of estrogens is impairment of their enterohepatic circulation. This may be due to absorption of biliary estrogen conjugates (e.g., by cholestyramine) or to insufficient cleavage of the conjugate by intestinal bacteria, the latter being observed after administration of antibiotics (e.g., ampicillin, neomycin). 1994-11 /pmc/articles/PMC1566787/ /pubmed/7698081 Text en
spellingShingle Research Article
Bolt, H M
Interactions between clinically used drugs and oral contraceptives.
title Interactions between clinically used drugs and oral contraceptives.
title_full Interactions between clinically used drugs and oral contraceptives.
title_fullStr Interactions between clinically used drugs and oral contraceptives.
title_full_unstemmed Interactions between clinically used drugs and oral contraceptives.
title_short Interactions between clinically used drugs and oral contraceptives.
title_sort interactions between clinically used drugs and oral contraceptives.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1566787/
https://www.ncbi.nlm.nih.gov/pubmed/7698081
work_keys_str_mv AT bolthm interactionsbetweenclinicallyuseddrugsandoralcontraceptives